Differences in the imaging of Erdheim-Chester disease using FDG-PET/CT, NaF-PET/CT examinations, and skeletal scintigraphy. Regression of the disease after treatment with cladribine combined with cyclophosphamide and anakinra
Authors:
doc. MUDr. Řehák Zdeněk, Ph.D. 1; MUDr. Stejskal Václav, Ph.D. 2; prof. MUDr. Adam Zdeněk, CSc. 3; MUDr. Kamarádová Kateřina, Ph.D. 2; MUDr. Štěpánková Pavla 4; MUDr. Soboličová Sandra 1; MUDr. Ošmera Pavel 1; MUDr. Starý Karel 5; MUDr. Nehyba Svatopluk, Ph.D. 6; MUDr. Čermák Aleš, Ph.D. 7; MUDr. Standara Michal 8,9; prof. MUDr. Pour Luděk, Ph.D. 3
Authors‘ workplace:
Oddělení nukleární medicíny, MOU Brno
1; Fingerlandův ústav patologie, LF UK a FN Hradec Králové
2; Interní hematologická a onkologická klinika LF MU a FN Brno
3; Hematologická klinika LF UK a FN Hradec Králové
4; Interní gastroenterologická klinika LF MU a FN Brno
5; Interní kardiologická klinika LF MU a FN Brno
6; Urologická klinika LF MU a FN Brno
7; Oddělení radiologie, MOÚ Brno
8; Klinika zobrazovacích metod LF MU, Brno
9
Published in:
Klin Onkol 2026; 39(3): 199-211
Category:
Case Report
doi:
https://doi.org/10.48095/ccko2026199
Overview
Background: Erdheim-Chester disease (ECD) is a rare disorder characterized by infiltrates of foamy histiocytes (histiocytes with abundant lipid inclusions – foamy cells) and inflammatory stroma, which induce a systemic inflammatory response. The disease typically infiltrates the bones causing osteosclerotic and mixed lesions with the characteristic “hot knees” pattern – increased uptake of radiopharmaceuticals in the epiphyses of bones near the knee joint. Observation: The patient had histologically confirmed ECD with negative test results for mutations in the BRAF gene and MEK pathway, but with aberrant cyclin D1 expression. The disease manifested with retrobulbar infiltrates, pericardial effusion, infiltration of the pancreas, retroperitoneum, and nerve roots. Secretion from the pericardial drain decreased after administration of high doses of methylprednisolone, followed by regular applications of anakinra. Extent of the disease was assessed by MRI of the head, PET/CT with the radiopharmaceuticals fluorodeoxyglucose (FDG) and sodium fluoride (NaF), and skeletal scintigraphy. FDG accumulated significantly in pathological infiltrates visible on low-dose CT. A pathological lesion with increased FDG accumulation was also present in the pituitary gland. FDG also showed increased accumulation in the bones, but the typical “hot knees” pattern was not present. This pattern, however, was visible on skeletal scintigraphy, and osteosclerotic lesions were most precisely detected using NaF-PET/CT. Treatment with interferon-alpha was unsuccessful. For second-line treatment, cladribine was used – in the first two cycles as monotherapy, and in the third and fourth cycles in combination with a low dose of cyclophosphamide. After the fourth cycle, symptoms of the disease regressed, and FDG-PET/CT showed disappearance or a significant reduction of pathological FDG accumulation in the disease lesions. Cladribine will be administered for a maximum of six cycles. Conclusion: FDG-PET/CT is currently the most appropriate examination for determining the extent of the disease as well as for assessing treatment response. However, the extent of osteosclerotic lesions, including the characteristic “hot knees” pattern, is more accurately visualized using NaF-PET/CT. Cladribine is an effective drug for both Langerhans cell histiocytosis and ECD. The therapeutic effect of cladribine, as well as its side effects, can be enhanced by adding cyclophosphamide. The inflammatory reaction induced by ECD was suppressed with anakinra.
Keywords:
anakinra – Erdheim-Chester disease – cladribine – FDG-PET/CT – NaF-PET/CT – skeletal scintigraphy
Sources
1. Goyal G, Heaney ML, Collin M et al. Erdheim-Chester disease: consensus recommendations for evaluation, diag-nosis, and treatment in the molecular era. Blood 2020; 135 (22): 1929–1945. doi: 10.1182/blood.2019003507.
2. Khoury JD, Solary E, Abla O et al. The 5th edition of the World Health Organization classification of haematolymphoid tumours: myeloid and histiocytic/dendritic neoplasms. Leukemia 2022; 36 (7): 1703–1719. doi: 10.1038/s41375-022-01613-1.
3. Oskarsdottir AR, Ravindran A, Koster MJ et al. Cyclin D1 overexpression with cytoplasmic localization distinguishes Erdheim-Chester disease from reactive histiocytic infiltrates. Am J Surg Pathol 2026; 50 (3): 273–282. doi: 10.1097/PAS.0000000000002506.
4. Diamond EL, Dagna L, Hyman DM et al. Consensus guidelines for the diagnosis and clinical management of erdheim-chester disease. Blood 2014; 124 (4): 483–492. doi: 10.1182/blood-2014-03-561381.
5. Chester W. Über Lipoidgranulomatose. Virchows Arch Für Pathol Anat 1930; 279 (2): 561–602.
6. Franco P, Filippi AR, Ciammella P et al. Polyostotic sclerosing histiocytosis (Erdheim-Chester disease) treated with combined vertebroplasty and radiation therapy. Tumori 2010; 96 (4): 633–636. doi: 10.1177/030089161009600421.
7. Cohen-Aubart F, Emile JF, Carrat F et al. Phenotypesand survival in Erdheim-Chester disease: Results froma 165-patient cohort. Am J Hematol 2018; 93 (5): E114––E117. doi: 10.1002/ajh.25055.
8. Sahu AK, Tripathy SR, Parida MK et al. Adult-onset asthma with periocular xanthogranuloma (AAPOX) associated with IgG4-related disorder: a case report and review of current literature. Cureus 2025; 17 (4): e82617. doi: 10.7759/cureus.82617.
9. Huang Q, Chen Z. Asymmetric adult-onset asthma with periocular xanthogranuloma (AAPOX) associated with IgG4-related disease: a case report. Front Surg 2026; 12 : 1753451. doi: 10.3389/fsurg.2025.1753451.
10. Haroche J, Cohen-Aubart F, Charlotte F et al. The histiocytosis Erdheim-Chester disease is an inflammatory myeloid neoplasm. Expert Rev Clin Immunol 2015; 11 (9): 1033–1042. doi: 10.1586/1744666X.2015.1060857.
11. Papo M, Diamond EL, Cohen-Aubart F et al. High prevalence of myeloid neoplasms in adults with non-langerhans cell histiocytosis. Blood 2017; 130 (8): 1007–1013. doi: 10.1182/blood-2017-01-761718.
12. Chaudhary R, Kumar A, Singh A et al. Erdheim-Chester disease: comprehensive insights from genetic mutations to clinical manifestations and therapeutic advances. Dis Mon 2025; 71 (2): 101845. doi: 10.1016/j.disamonth.2024.101845.
13. Pegoraro F, Cohen-Aubart F, Papo M et al. MEK inhibitors are effective in Erdheim-Chester disease regardless of MAPK pathway mutations. Leukemia 2025; 39 (6): 1540–1542. doi: 10.1038/s41375-025-02614-6.
14. Goyal G, Acosta-Medina AA, Go RS et al. Molecular profiling is critical to guide MEK inhibitor use in Erdheim-Chester disease. Leukemia 2025; 39 (9): 2306–2307. doi: 10.1038/s41375-025-02704-5.
15. Durham BH. Molecular pathogenesis of the histiocytic and dendritic cell neoplasms. Hematol Oncol Clin North Am 2025; 39 (3): 471–490. doi: 10.1016/j.hoc.2025.03.001.
16. Adam Z, Řehák Z, Keřkovský M et al. Monoklonální gamapatie klinického významu s osteosklerotickými ložisky – popis případu a přehled literatury. Klin Onkol 2024; 37 (3): 209–219. doi: 10.48095/ccko2024209.
17. Minařík J, Ščudla V, Bačovský J et al. Comparison of imaging methods in POEMS syndrome. Biomed Pap Med Fac Univ Palacky Olomouc Czech Repub 2012; 156 (1): 52–57. doi: 10.5507/bp.2011.053.
18. Raynor WY, Borja AJ, Hancin EC et al. Novel musculoskeletal and orthopedic applications of 18F-sodium fluoride PET. PET Clin 2021; 16 (2): 295–311. doi: 10.1016/j.cpet.2020.12.006.
19. Adam Z, Mayer J, Pour l et al. Autoinflamatorní choroby se symptomy, které připomínají maligní krevní choroby – syndrom Schnitzlerové, Stillova choroba dospělých, SAPHO a VEXAS syndrome. Trans Hematol Dnes 2024; 30 (3): 151–168. 10.48095/cctahd2024prolekare.cz13.
20. Caoduro C, Ungureanu CM, Rudenko B et al. 18F-fluoride PET/CT aspect of an unusual case of Erdheim-Chester disease with histologic features of langerhans cell histiocytosis. Clin Nucl Med 2013; 38 (7): 541–542. doi: 10.1097/RLU.0b013e318270830f.
21. Sabino D, do Vale RH, Duarte PS et al. Complementary findings on 18F-FDG PET/CT and 18F-NaF PET/CT in a patient with Erdheim-Chester disease. Radiol Bras 2017; 50 (3): 202–203. doi: 10.1590/0100-3984.2015.0172.
22. Chiocchi M, Luciano A, De Stasio V et al. Radiological findings in Erdheim Chester disease: a very rare multisistemic disease. Radiol Case Rep 2023; 18 (5): 2047–2054. doi: 10.1016/j.radcr.2023.02.063.
23. Antunes C, Graça B, Donato P et al. Thoracic, abdominal and musculoskeletal involvement in Erdheim-Chester disease: CT, MR and PET imaging findings. Insights Imaging 2014; 5 (4): 473–482. doi: 10.1007/s13244-014-0331-7.
24. Aswani Y, Patel A, Zhan X et al. Imaging in Erdheim-Chester disease. Radiographics 2024; 44 (9): e240011. doi: 10.1148/rg.240011.
25. Bountas D, Bountas M, Exadactylou P et al. Erdheim--Chester disease and nuclear medicine imaging. a case report and brief review. Skeletal Radiol 2025; 54 (2): 359–365. doi: 10.1007/s00256-024-04718-z.
26. Nikpanah M, Dehghani Firouzabadi F, Farhadi F et al. Skeletal involvement in Erdheim-Chester disease: multimodality imaging features and association with the BRAF. Clin Imaging 2024; 106 : 110067. doi: 10.1016/j.clinimag.2023.110067.
27. Kim M, Rowe SP, Mehta TI et al. Erdheim-Chester disease occult on radiographs and CT but visible on MRI and PET. Am J Case Rep 2024; 25: e941169. doi: 10.12659/AJCR.941169.
28. Azhideh A, Pouramini A, Haseli S et al. Radiological assessment of extremity bone involvement in Erdheim--Chester disease: a systematic review of case reports. Skeletal Radiol 2025; 54 (7): 1441–1455. doi: 10.1007/s00256-024-04835-9.
29. Uliel L, Schattner A, Nissim E et al. Unilateral leg edema: Erdheim-Chester disease. QJM 2020; 113 (2): 115–117. doi: 10.1093/qjmed/hcz237.
30. Chazal T, Pegoraro F, Manari G et al. Clinical phenotypes and long-term outcome of kidney involvement in Erdheim-Chester histiocytosis. Kidney Int 2023; 103 (1): 177–186. doi: 10.1016/j.kint.2022.09.027.
31. Burke SE, Chaudhry A, Kaya EA et al. Urologic manifestations and hydronephrosis as initial presentation of Erdheim-Chester disease: a rare form of non--langerhans histiocytosis. Cureus 2021; 13 (11): e19750. doi: 10.7759/cureus.19750.
32. Czeyda-Pommersheim F, Menias C, Boustani A et al. Diagnostic approach to primary retroperitoneal pathologies: what the radiologist needs to know. Abdom Radiol (NY) 2021; 46 (3): 1062–1081. doi: 10.1007/s00261-020-02752-8.
33. Vanhomwegen C, Mestrez F, Faverly D et al. Indolent renal involvement with BRAF. Clin Case Rep 2021; 9 (8): e04683. doi: 10.1002/ccr3.4683.
34. Dion E, Graef C, Haroche J et al. Imaging of thoracoabdominal involvement in Erdheim-Chester disease. AJR Am J Roentgenol 2004; 183 (5): 1253–1260. doi: 10.2214/ajr.183.5.1831253.
35. Wang S, Li J, Ren Y et al. Extensive pulmonary cyst formation in Erdheim-Chester disease. Am J Respir Crit Care Med 2022; 206 (12): 1546–1547. doi: 10.1164/rccm.202206-1138IM.
36. Miao HL, Chang L, Lin H et al. Patterns and organ treatment response of Erdheim-Chester disease with cardiac involvement. Heart 2024; 110 (13): 899–907. doi: 10.1136/heartjnl-2024-323867.
37. Haroche J, Cluzel P, Toledano D et al. Images in cardiovascular medicine. Cardiac involvement in Erdheim-Chester disease: magnetic resonance and computed tomographic scan imaging in a monocentric series of 37 patients. Circulation 2009; 119 (25): e597–598. doi: 10.1161/CIRCULATIONAHA.108.825075.
38. Ritter A, Meier J, Angst F et al. Erdheim-Chester disease: hairy kidney and coated aorta. Kidney Int 2023; 103 (2): 431. doi: 10.1016/j.kint.2022.09.016.
39. Ouattara TR, Pezel T, Lorillon G et al. Case report: relapsing pleural effusions and coated aorta revealing Erdheim-Chester disease. Front Immunol 2025; 16 : 1585541. doi: 10.3389/fimmu.2025.1585541.
40. Wong A, Sharma A, Ramcharitar R. et al. Cardiovascular manifestations of Erdheim-Chester disease: a narrative review with two cases. Vasc Med 2024; 29 (3): 313–319. doi: 10.1177/1358863X241228271.
41. Lakhani PM, Borysiewicz C, Mason J. Erdheim-Chester disease: a rare cause of bilateral renal artery stenosis, mimicking large vessel vasculitis. BMJ Case Rep 2022; 15 (3): e242393. doi: 10.1136/bcr-2021-242393.
42. Kanakis M, Petrou P, Lourida G et al. Erdheim-Chester disease: a comprehensive review from the ophthalmologic perspective. Surv Ophthalmol 2022; 67 (2): 388–410. doi: 10.1016/j.survophthal.2021.05.013.
43. El Fakih F, Abramowicz S, Toutée A et al. Chorioidal infiltration in Erdheim Chester disease: a case series. Retin Cases Brief Rep 2026; 20 (1): 84–90. doi: 10.1097/ICB.0000000000001676.
44. Brodie J, Zhou S, Makkuni D et al. Erdheim-Chester disease: two cases from an ophthalmic perspective. Am J Ophthalmol Case Rep 2020; 20 : 100984. doi: 10.1016/j.ajoc.2020.100984.
45. Lauricella E, d‘Amati A, Ingravallo G et al. Cerebellar ataxia and exercise intolerance in Erdheim--Chester disease. Cerebellum Ataxias 2021; 8 (1): 3. doi: 10.1186/s40673-020-00125-x.
46. Drouillard M, Trunet S, Hervochon R et al. Sinonasal and ear manifestations of Erdheim-Chester disease. Br J Haematol 2023; 203 (2): 194–201. doi: 10.1111/bjh.18963.
47. Dunkerton S, Penninkilampi R, Beadnall H et al. Erdheim-Chester disease presenting as precipitous cognitive decline. Pract Neurol 2023; 23 (1): 91–92. doi: 10.1136/pn-2022-003504.
48. Filizoglu N, Ozguven S, Ones T et al. Central nervous system complications of Erdheim-Chester disease: FDG PET/CT findings. Clin Nucl Med 2021; 46 (7): e387–e388. doi: 10.1097/RLU.0000000000003531.
49. Qazi MS, Ahmad A, Mukhtiar M et al. Neurological manifestations of Erdheim-Chester disease and their management: a scoping review. Medicine (Baltimore) 2025; 104 (12): e41932. doi: 10.1097/MD.0000000000041932.
50. García-Gómez FJ, Acevedo-Báñez I, Martínez-Castillo R et al. The role of 18FDG, 18FDOPA PET/CT and 99mtc bone scintigraphy imaging in Erdheim-Chester disease. Eur J Radiol 2015; 84 (8): 1586–1592. doi: 10.1016/j.ejrad.2015.04.022.
51. Makras P, Erickson D, Davidge-Pitts CJ et al. Approach to the patient: from endocrinopathy to the diagnosis of a histiocytic disorder. J Clin Endocrinol Metab 2025; 110 (6): 1756–1766. doi: 10.1210/clinem/dgae827.
52. Courtillot C, Laugier Robiolle S, Cohen Aubart F et al. Endocrine manifestations in a monocentric cohort of 64 patients with Erdheim-Chester disease. J Clin Endocrinol Metab 2016; 101 (1): 305–313. doi: 10.1210/jc.2015-3357.
53. Haroche J, Amoura Z, Touraine P et al. Bilateral adrenal infiltration in Erdheim-Chester disease. Report of seven cases and literature review. J Clin Endocrinol Metab 2007; 92 (6): 2007–2012. doi: 10.1210/jc.2006-2018.
54. Sheu SY, Wenzel RR, Kersting C et al. Erdheim-Chester disease: case report with multisystemic manifestations including testes, thyroid, and lymph nodes, and a review of literature. J Clin Pathol 2004; 57 (11): 1225–1228. doi: 10.1136/jcp.2004.018481.
55. Rafiee MJ, Taylor J, Hickeson M et al. Pancreatic involvement in Erdheim-Chester disease: rare presentation of a rare disease. Radiol Case Rep 2023; 18 (5): 1809–1820. doi: 10.1016/j.radcr.2023.02.012.
56. Gupta A, Aman K, Al-Babtain M. et al. Multisystem Erdheim-Chester disease; a unique presentation with liver and axial skeletal involvement. Br J Haematol 2007; 138 (3): 280. doi: 10.1111/j.1365-2141.2007.06642.x.
57. Pan A, Doyle T, Schlup M et al. Unusual manifestation of Erdheim-Chester disease. BMC Gastroenterol 2011; 11 : 77. doi: 10.1186/1471-230X-11-77.
58. Kobic A, Shah KK, Schmitt AR et al. Erdheim-Chester disease: expanding the spectrum of cutaneous manifestations. Br J Dermatol 2020; 182 (2): 405–409. doi: 10.1111/bjd.18153.
59. Řehák Z, Koukalová R, Vašina J et al. 18F-FDG PET/CT obraz Erdheimovy-Chesterovy nemoci – přehled českých pacientů. Nukl Med 2018; 7 (3): 50–56.
60. Kinkor Z. Závažné plicní postižení u Erdheim-Chesterovy nemoci (kazuistika). Česko-slov Patol Soudní Lék 2001; 37 : 114–117.
61. Wu S, Pang Y, Chen Y et al. 68Ga-dota-fapi-04 PET/CT in Erdheim-Chester disease. Clin Nucl Med 2021; 46 (3): 258–260. doi: 10.1097/RLU.0000000000003491.
62. Ma J, Yang Q, Huo L et al. Performance of 68Ga-labeled fibroblast activation protein inhibitor PET/CT in evaluation of Erdheim-Chester disease: a comparison with 18F--FDG PET/CT. J Nucl Med 2023; 64 (9): 1985–1391. doi: 10.2967/jnumed.123.265691.
63. Zhang W, Wu Y, Guo L et al. [68Ga]Ga-FAPI PET/CT in the evaluation of Langerhans cell histiocytosis: comparison with 18F FDG PET/CT. Eur J Nucl Med Mol Imaging 2025; 52 (6): 2187–2197. doi: 10.1007/s00259-025-07097-2.
64. Wilcox SR, Reynolds SB, Ahmed AZ. Erdheim-Chester disease: investigating the correlation between targeted treatment therapy and disease outcomes. Cancers (Basel) 2024; 16 (7): 1299. doi: 10.3390/cancers16071299.
65. Pegoraro F, Cohen-Aubart F, Papo M et al. MEK inhibitors are effective in Erdheim-Chester disease regardless of MAPK pathway mutations. Leukemia 2025; 39 (6): 1540–1542. doi: 10.1038/s41375-025-02614-6.
66. Aromolo IF, Moltrasio C, Maronese CA et al. Successful treatment of cutaneous-onset Erdheim-Chester disease with cobimetinib and anakinra. Clin Exp Dermatol 2024; 49 (5): 523–525. doi: 10.1093/ced/llae014.
67. Goyal G, Reiner AS, Bossert D et al. Long-term outcomes with single-agent BRAF inhibitor therapy in Erdheim-Chester disease. Blood 2025; 145 (18): 2100–2103. doi: 10.1182/blood.2024028032.
Labels
Paediatric clinical oncology Surgery Clinical oncologyArticle was published in
Clinical Oncology
2026 Issue 3
Most read in this issue
- Clinical presentations of the most common histiocytic disorders
- Jaký časopis Klinická onkologie chceme?
- Second and subsequent lines of systemic therapy in endometrial cancer – a real-life clinical experience
- 68Ga-DOTATOC PET/CT – a case report of synchronous oncological duplicity with high expression of somatostatin receptors